Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy

Xia, Wu-Yan; Zhu, Xinjian; Feng, Wen; Liu, Jun; Wang, Jiaming; Lv, Chao; Zhang, Qin; Wen, Yu; Cai, Xu-Wei; Fu, Xiaolong

doi:10.21037/tlcr-20-831

Cited by 15 publications

(25 citation statements)

References 34 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging studies indicated that NLR is an effective predictor of prognosis, response to therapy, recurrence in various malignancies. 2–10 Some studies have also shown that NLR associated with prognosis and treatment response in cardiovascular diseases. 11–14 In addition, other researchers have found that NLR levels association with diagnosis and prognosis of infectious diseases such as community-acquired pneumonia, 15 bacteremia, and sepsis.…”

Section: Introductionmentioning

confidence: 99%

Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality and Cause-Specific Mortality in US Adults, 1999–2014

Chen¹,

Wang²,

Zeng³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background Neutrophil-lymphocyte ratio (NLR) is a novel marker of inflammation. Emerging studies have evaluated the relationship of NLR with cardiovascular diseases and malignant conditions. However, rare studies regarded the association between NLR and long-term health status. This study aimed to evaluate the association of NLR with all-cause mortality and cause-specific mortality among adults in the United States. Methods We obtained eight cycles data of National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2014, and enrolled 32328 participants after certain screening. By weighted chi-square test and linear regression analysis, we analyzed the correlation between NLR and baseline characteristics of the participants. Kaplan–Meier curves and Cox regression models were used to assess the survival relevance of NLR. We conducted stratified analysis, interaction analysis, and sensitivity analysis to robustness of our results. Results Participants with high NLR levels had a higher risk of death. After adjustment for baseline characteristics, the hazard ratio comparing the higher vs lower NLR levels was 1.43 (95% CI, 1.18–1.73) for all-cause mortality, 1.27 (95% CI, 0.84–1.92) for cancer mortality, and 1.44 (95% CI, 0.96–2.16) for cardiovascular disease mortality. Stratified analysis found that the observed associations between NLR levels and mortality did not differ significantly. Conclusion In this nationally representative cohort of US adults, higher NLR was significantly associated with an increased risk of all-cause mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality and Cause-Specific Mortality in US Adults, 1999–2014

Chen¹,

Wang²,

Zeng³

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…Several studies demonstrated that systemic in ammatory biomarkers in peripheral blood were predictive markers for treatment outcomes in different solid tumors including prostate, colorectal, and esophageal cancer, melanoma, and NSCLC [15][16][17][18][19]. Although the exact biological basis for these ndings has not been thoroughly elucidated, in ammatory cells such as neutrophils play a signi cant role in tumor development and progression via effects on tumor cells or other components of the tumor microenvironment by secreting chemokines and cytokines such as transforming growth factor-ß, interleukin-6 (IL-6), and matrix metalloproteinase [20,21].…”

Section: Discussionmentioning

confidence: 99%

Significance of Glasgow prognostic scores in NSCLC patients treated with immunotherapy after platinum-based cytotoxic chemotherapy

Kang

Shin

Yeo

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The Glasgow prognostic score (GPS) reflects the host’s systemic inflammatory response and is a validated prognostic factor in lung cancer. However, little is known about the prognostic role in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy.Methods: This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020. We included patients who were diagnosed with unresectable advanced stage NSCLC or recurrent disease after pulmonary resection and had received at least one regimen of platinum-based chemotherapy before the administration of immunotherapy. The prognostic value of the GPS was assessed in patients with NSCLC treated with anti-PD1 or anti-PD-L1 (pembrolizumab, nivolumab, or atezolizumab). The GPS was calculated using C-reactive protein and albumin concentrations within one week before starting anti-PD1 or anti-PD-L1 treatment. Results: A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy after platinum-based chemotherapy were included in the study. Kaplan-Meier analysis revealed that higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) (log-rank P < 0.001) and overall survival (OS) (log-rank P < 0.001). In the Cox regression multivariate analysis, the hazard ratios for irPFS were 0.249 (95% confidence interval [CI]: 0.084 – 0.739, P = 0.012) for PD-L1 expression ≥ 50% and 9.73 (95% CI: 2.931 – 32.298, P < 0.001) for a GPS of 2 relative to a GPS of 0. Older age (P = 0.033), lower PD-L1 expression (P = 0.036), and higher GPS values (P = 0.007) were independently associated with shorter OS.Conclusions: Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy after platinum-based chemotherapy.

show abstract

“…Several studies have demonstrated that systemic inflammatory biomarkers in peripheral blood were predictive markers for treatment outcomes in different solid tumors including prostate, colorectal, and esophageal cancer, melanoma, and NSCLC (22)(23)(24)(25)(26). Although the exact biological basis for these findings has not been thoroughly elucidated, inflammatory cells such as neutrophils play a significant role in tumor development and progression via effects on tumor cells or other components of the tumor microenvironment, by secreting chemokines and cytokines such as transforming growth factor-β, interleukin-6 (IL-6) and matrix metalloproteinases (27,28).…”

Section: Discussionmentioning

confidence: 99%

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy

Kang

Shin

Yeo

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background/Aim: Little is known about the prognostic role of the Glasgow prognostic score (GPS) in nonsmall cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy. Patients and Methods: This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020. Results: A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy were included. Higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) and overall survival (OS). The hazard ratios for irPFS were 0.249 for programmed death-ligand 1 (PD-L1) expression ≥50% and 9.73 for a GPS of 2. Older age, lower PD-L1 expression and higher GPS values were independently associated with shorter OS. Conclusion: Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.The introduction of immune-checkpoint inhibitors (ICIs) into the therapy for non-small cell lung cancer (NSCLC) has transformed the therapeutic landscape of metastatic NSCLC (1). The expression of programmed death-ligand 1 (PD-L1) on tumor cells and tumor mutation burden (TMB) have been used to select patients suitable for ICIs but not all patients with these predictive factors benefit from ICIs (2). However, the proper predictive factors for using ICIs to treat NSCLC patients have not been developed.Inflammation is an important factor in tumor progression and is associated with poor response to treatment. The response to cancer treatment depends not only on the tumor's characteristics and tumor stage but also on patient-related factors including nutrition and inflammation status (3). Recently, systemic inflammatory response to predict progression and survival has been reported in patients with malignancies. Thus, cancer-related prognosis has been validated using inflammatory markers such as the neutrophillymphocyte ratio (NLR) or the lung immune prognostic index 3423 This article is freely accessible online.

show abstract

Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy

Cited by 15 publications

References 34 publications

Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality and Cause-Specific Mortality in US Adults, 1999–2014

Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality and Cause-Specific Mortality in US Adults, 1999–2014

Significance of Glasgow prognostic scores in NSCLC patients treated with immunotherapy after platinum-based cytotoxic chemotherapy

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy

Contact Info

Product

Resources

About